TLR5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29546960	1.00	3/20
SCHEMBL9042411	0.46	3/20
SCHEMBL16281249	0.46	3/20
SCHEMBL30093319	0.46	3/20
SCHEMBL14090789	0.44	3/20
SCHEMBL14115537	0.44	3/20
SCHEMBL20609579	0.44	3/20
SCHEMBL14975039	0.43	3/20
SCHEMBL24623997	0.42	3/20
SCHEMBL1322519	0.42	3/20
SCHEMBL25462134	0.41	3/20
SCHEMBL25462135	0.41	3/20
SCHEMBL2855389	0.39	3/20
SCHEMBL25462114	0.39	3/20
SCHEMBL25462116	0.39	3/20
SCHEMBL16195089	0.39	3/20
SCHEMBL30945296	0.37	3/20
SCHEMBL15703253	0.53	2/20
SCHEMBL17268797	0.48	2/20
SCHEMBL17268782	0.48	2/20

Clinical trials — most relevant to TLR5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic	PHASE2/PHASE3	WITHDRAWN
Kabul Vitamin D Supplementation Trial	PHASE3	UNKNOWN
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients	PHASE1/PHASE2	COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers	PHASE1	COMPLETED
Personalized Multi-peptide Vaccination in CLL Patients	PHASE1	COMPLETED
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.	PHASE1	COMPLETED
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer	EARLY_PHASE1	COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19	nan	COMPLETED
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection	nan	COMPLETED
Neuro-Immune Interactions in the Gut	nan	COMPLETED
TLR4 Polymorphisms and Risk of Skin Cancer	nan	COMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients	nan	UNKNOWN
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Mucins and Toll-like Receptors in Asthma	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Bacteremia in Intensive Care Unit (ICU)	nan	UNKNOWN
The Suppression of Toll Like Receptors by Insulin	nan	COMPLETED
X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study	nan	COMPLETED
Nasal Immune Challenge Study	nan	UNKNOWN
Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation	nan	UNKNOWN
Innate Immune Response in COPD	nan	COMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis	nan	UNKNOWN
Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)	nan	UNKNOWN
Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans	nan	COMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients	nan	COMPLETED
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TLR5 binder may also engage these)

Protein	Name	Similarity
Q9JLF7	—	1.000	Q9JLF7 →
Q2V898	—	0.991	Q2V898 →
Q9TSP2	—	0.990	Q9TSP2 →
Q9GL65	—	0.989	Q9GL65 →
P58682	—	0.989	P58682 →
Q9TTN0	—	0.989	Q9TTN0 →
Q8SPE8	—	0.988	Q8SPE8 →
TLR4	Toll-like receptor 4	0.988	landscape →
Q68Y56	—	0.987	Q68Y56 →
Q9QX05	—	0.987	Q9QX05 →
Q9MYW3	—	0.987	Q9MYW3 →
Q0PV50	—	0.986	Q0PV50 →
TLR3	Toll-like receptor 3	0.985	landscape →
Q99MB1	—	0.984	Q99MB1 →
Q5TJ59	—	0.984	Q5TJ59 →
P58727	—	0.984	P58727 →
TLR8	Toll-like receptor 8	0.984	landscape →
Q8SPE9	—	0.984	Q8SPE9 →
Q9QUK6	—	0.983	Q9QUK6 →
E5DHB5	—	0.981	E5DHB5 →
Q9WV82	—	0.981	Q9WV82 →
Q99467	—	0.979	Q99467 →
Q6R5N8	—	0.979	Q6R5N8 →
Q62192	—	0.979	Q62192 →
P28653	—	0.979	P28653 →
Q9EQU3	—	0.978	Q9EQU3 →
Q58A48	—	0.978	Q58A48 →
Q9R1F8	—	0.978	Q9R1F8 →
P58681	—	0.978	P58681 →
Q95M53	—	0.978	Q95M53 →